IL2 and metastatic melanoma: Here, we report the results of a phase II study of 12 patients with metastatic melanoma treated with a modified ACT protocol utilizing autologous TIL with preconditioning chemotherapy followed by the administration of subcutaneous IL-2 administered at a low dose of 125,000 IU/kg/day over 12 days.